Biocardia Stock Alpha and Beta Analysis
| BCDA Stock | USD 2.60 0.03 1.17% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Biocardia. It also helps investors analyze the systematic and unsystematic risks associated with investing in Biocardia over a specified time horizon. Remember, high Biocardia's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Biocardia's market risk premium analysis include:
Beta 0.0 | Alpha 0.0 | Risk 5.89 | Sharpe Ratio 0.0893 | Expected Return 0.53 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Biocardia |
Biocardia Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Biocardia market risk premium is the additional return an investor will receive from holding Biocardia long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Biocardia. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Biocardia's performance over market.| α | 0.00 | β | 0.00 |
Biocardia expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Biocardia's Buy-and-hold return. Our buy-and-hold chart shows how Biocardia performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Biocardia Market Price Analysis
Market price analysis indicators help investors to evaluate how Biocardia stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Biocardia shares will generate the highest return on investment. By understating and applying Biocardia stock market price indicators, traders can identify Biocardia position entry and exit signals to maximize returns.
Biocardia Return and Market Media
The median price of Biocardia for the period between Sun, Dec 15, 2024 and Sat, Mar 15, 2025 is 2.28 with a coefficient of variation of 9.39. The daily time series for the period is distributed with a sample standard deviation of 0.22, arithmetic mean of 2.3, and mean deviation of 0.18. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 3257 shares by Edward Gillis of Biocardia at 2.0 subject to Rule 16b-3 | 12/20/2024 |
2 | Acquisition by Peter Altman of 1000 shares of Biocardia at 2.06 subject to Rule 16b-3 | 12/23/2024 |
3 | Biocardia senior vice president Edward Gillis sells 6,514 in stock - Investing.com | 12/26/2024 |
4 | BioCardia, Inc. Short Interest Down .6 percent in December | 01/17/2025 |
5 | Acquisition by Peter Altman of 500 shares of Biocardia at 2.4 subject to Rule 16b-3 | 01/29/2025 |
6 | Acquisition by Peter Altman of 2 shares of Biocardia at 2.38 subject to Rule 16b-3 | 01/30/2025 |
7 | 12 Health Care Stocks Moving In Mondays Pre-Market Session - Benzinga | 02/03/2025 |
8 | Acquisition by Peter Altman of 600 shares of Biocardia at 2.48 subject to Rule 16b-3 | 02/07/2025 |
9 | Biocardia CEO Peter Altman acquires 1,488 in stock - Investing.com | 02/11/2025 |
10 | Acquisition by Peter Altman of 500 shares of Biocardia at 2.11 subject to Rule 16b-3 | 03/03/2025 |
11 | BioCardia, Inc. Director Simon H. Stertzer Acquires 22,753 Shares | 03/05/2025 |
12 | Reviewing BioCardia Moderna - Defense World | 03/12/2025 |
About Biocardia Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Biocardia or other stocks. Alpha measures the amount that position in Biocardia has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | Dividend Yield | 0.0338 | 0.03 | Price To Sales Ratio | 33.91 | 32.21 |
Biocardia Upcoming Company Events
As portrayed in its financial statements, the presentation of Biocardia's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Biocardia's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Biocardia's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Biocardia. Please utilize our Beneish M Score to check the likelihood of Biocardia's management manipulating its earnings.
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Biocardia
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Biocardia Backtesting, Biocardia Valuation, Biocardia Correlation, Biocardia Hype Analysis, Biocardia Volatility, Biocardia History and analyze Biocardia Performance. For information on how to trade Biocardia Stock refer to our How to Trade Biocardia Stock guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Biocardia technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.